BioTuesdays

Category - Markets

Theratechnologies
Markets

CIBC ups Theratechnologies PT to $15 from $10.30

CIBC World Markets raised its price target for Theratechnologies (TSX:TH) to $15 from $10.30 after the FDA approved Trogarzo for the treatment of multi-drug resistant HIV patients. The stock was quoted at $9.35 in...

March 7, 2018
Markets

Maxim lowers BioLineRx PT to $2 from $3

Maxim Group reduced its price target for BioLineRx (NASDAQ:BLRX) to $2 from $3 after the company reported fourth quarter results. The stock was quoted at $1 in afternoon trading on March 6. BioLineRx, which focuses on...

March 6, 2018
Obalon Therapeutics
Markets

BTIG cuts Obalon Therapeutics PT to $7 from $13

BTIG lowered its price target for Obalon Therapeutics (NASDAQ:OBLN) to $7 from $13 after the company reported in-line fourth quarter results and guidance for 2018. The stock finished at $4.01 on March 5. Obalon is...

March 6, 2018
Vericel Logo
Markets

BTIG ups Vericel PT to $13 from $8

BTIG raised its price target for Vericel (NASDAQ:VCEL) to $13 from $8 after the company beat consensus estimates for the fourth quarter and provided strong guidance for 2018. The stock was quoted at $11.15, up $2.80, in...

March 5, 2018
GTX
Markets

Stifel nearly triples PT for GTx to $45 from $16

Stifel nearly tripled its price target for GTx (NASDAQ:GTXI) to $45 from $16 after the company reported significant positive new data at the SUFU Winter Meeting for its Phase 2 proof-of-concept study testing, enobosarm...

March 5, 2018
Intec Pharma
Markets

Ladenburg starts Intec Pharma at buy; PT $13

Ladenburg Thalmann launched coverage of Intec Pharma (NASDAQ:NTEC) with a “buy” rating and $13 price target. The stock was quoted at $6 in early trading on March 1. Intec is leveraging its proprietary drug delivery...

March 1, 2018
Profound Medical Logo
Markets

Beacon starts Profound Medical at buy; PT $3.10

Beacon Securities initiated coverage of Profound Medical (TSXV:PRN) with a “buy” rating and 12-month price target of $3.10. The stock closed at $1 on Feb. 28. “We believe Profound Medical is a company who is building...

March 1, 2018
Novavax Logo
Markets

Ladenburg ups Novavax PT to $3.50 from $2.50

Ladenburg Thalmann raised its price target for Novavax (NASDAQ:NVAX) to $3.50 from $2.50 after the company presented Phase 1/2 data suggesting its NanoFlu vaccine has the potential to be the most potent product for...

March 1, 2018
Acer Therapeutics
Markets

Roth starts Acer Therapeutics at buy; PT $70

Roth Capital Partners launched coverage of Acer Therapeutics (NASDAQ:ACER) with a “buy” rating and price target of $70. The stock closed at $17.28 on Feb. 23. Acer’s focuses on vascular Ehlers-Danlos Syndromes (vEDS), a...

February 26, 2018
ArQule
Markets

Roth starts ArQule at buy; PT $5

Roth Capital Partners launched coverage of ArQule (NASDAQ:ARQL) with a “buy” rating and $5 price target. The stock closed at $1.67 on Feb. 21. “We believe that the value-driving components of the pipeline have been in...

February 22, 2018